CPA
HRTX icon

Capital Planning Advisors’s Heron Therapeutics HRTX Stock Holding History

Capital Planning Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-144,095
Closed -$187K – 158
2025
Q4 		$187K Hold
144,095
– – 0.03% 162
2025
Q3 		$182K Hold
144,095
– – 0.02% 143
2025
Q2 		$298K Buy
144,095
+6,000
+4% +$12.3K 0.04% 116
2025
Q1 		$304K Buy
138,095
+31,530
+30% +$61.2K 0.05% 117
2024
Q4 		$163K Buy
106,565
+31,003
+41% +$50.3K 0.03% 137
2024
Q3 		$150K Buy
75,562
+1,000
+1% +$2.39K 0.02% 139
2024
Q2 		$261K Buy
74,562
+10,742
+17% +$33K 0.04% 123
2024
Q1 		$177K Buy
63,820
+24,150
+61% +$60.7K 0.03% 141
2023
Q4 		$67.4K Buy
39,670
+26,200
+195% +$28.8K 0.01% 134
2023
Q3 		$13.9K Buy
+13,470
New +$19.2K ﹤0.01% 121

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Capital Planning Advisors's HRTX Position: Q1 2026 in Review

Capital Planning Advisors sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 144,095 shares — an estimated $187K sold.

Capital Planning Advisors first reported a position in HRTX in Q3 2023 and held it in 10 quarters. The position peaked at $304K in Q1 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Capital Planning Advisors reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Capital Planning Advisors sold 144,095 Heron Therapeutics shares in Q1 2026, an estimated $187K.
  • Capital Planning Advisors first reported a position in Heron Therapeutics in Q3 2023 and held it in 10 quarters.
  • Capital Planning Advisors's Heron Therapeutics position peaked at $304K in Q1 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Capital Planning Advisors's 13F filing for Q1 2026, filed 14 May 2026.